Rheumatoid arthritis gene therapy - University of Pittsburgh

Drug Profile

Rheumatoid arthritis gene therapy - University of Pittsburgh

Alternative Names: IL-1Ra gene therapy

Latest Information Update: 21 Jan 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Pittsburgh Medical Center
  • Class Antirheumatics; Gene therapies
  • Mechanism of Action Interleukin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 25 Feb 2002 A study has been added to the Rheumatoid arthritis pharmacodynamics sections
  • 16 May 2001 Phase-I clinical trials in Rheumatoid arthritis in USA (Intra-articular)
  • 29 Oct 1999 A study has been added to the adverse events and Rheumatoid arthritis pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top